News & Events: Immunosuppression

UCSF News reports on a clinical trial, BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial) where for the first time, an immunosuppressive agent,  Belatacept, showed better organ survival in kidney transplant recipients than a calcineurin inhibitor, the current standard of care. The study was reported on in the January 28th issue of the New England Journal of Medicine by lead author, Flavio Vincenti, MD, Clinical Professor of Medicine and Surgery in the Departments of Medicine and Surgery, and other researchers. For the first time, an [...]

UCSF News reports on the work of  Qizhi Tang, Ph.D., and other UC San Francisco researchers to develop new organ transplant strategies that better prevent rejection of donated organs. The research of Dr. Tang, Associate Professor in the Division of Transplant Surgery, and Director of the Transplantation Research Lab and Tang Lab, and colleagues, is reported on in two recently published journal articles. "Organ-transplant recipients often reject donated organs, but a new, two-pronged strategy developed by UC San Francisco researchers to specifically weaken immune responses that target [...]